T4 bacteriophage nanoparticles engineered through CRISPR provide a versatile platform for rapid development of flu mucosal vaccines
Authors:
- 27 July 2023
- journal article
- research article
- Published by Elsevier in Antiviral Research
- Vol. 217, 105688
Abstract
No abstract availableKeywords
All Related Versions
This publication has 60 references indexed in Scilit:
- Mutated and Bacteriophage T4 Nanoparticle Arrayed F1-V Immunogens from Yersinia pestis as Next Generation Plague VaccinesPLOS Pathogens, 2013
- Migratory properties of pulmonary dendritic cells are determined by their developmental lineageMucosal Immunology, 2013
- Bacteriophage adhering to mucus provide a non–host-derived immunityProceedings of the National Academy of Sciences, 2013
- Cutting Edge: Tissue-Retentive Lung Memory CD4 T Cells Mediate Optimal Protection to Respiratory Virus InfectionThe Journal of Immunology, 2011
- Intranasal Immunization with Influenza VLPs Incorporating Membrane-Anchored Flagellin Induces Strong Heterosubtypic ProtectionPLOS ONE, 2010
- Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infectionJournal of Experimental Medicine, 2010
- Phenotypic Definition of Effector and Memory T-Lymphocyte Subsets in Mice Chronically Infected withMycobacterium tuberculosisClinical and Vaccine Immunology, 2010
- Intranasal Vaccination with 1918 Influenza Virus-Like Particles Protects Mice and Ferrets from Lethal 1918 and H5N1 Influenza Virus ChallengeJournal of Virology, 2009
- Nanoparticles target distinct dendritic cell populations according to their sizeEuropean Journal of Immunology, 2008
- Coexpression of CD25 and OX40 (CD134) Receptors Delineates Autoreactive T-cells in Type 1 DiabetesDiabetes, 2006